| Literature DB >> 35320348 |
Mihir Rajurkar1, Aparna R Parikh1,2, Alexander Solovyov3, Eunae You1, Anupriya S Kulkarni1, Chong Chu4, Katherine H Xu1, Christopher Jaicks1, Martin S Taylor5, Connie Wu6,7, Katherine A Alexander8, Charly R Good8, Annamaria Szabolcs1, Stefanie Gerstberger2, Antuan V Tran4, Nova Xu1, Richard Y Ebright1, Emily E Van Seventer1, Kevin D Vo1, Eric C Tai1, Chenyue Lu1, Jasmin Joseph-Chazan1, Michael J Raabe1, Linda T Nieman1, Niyati Desai1, Kshitij S Arora1,5, Matteo Ligorio1,9, Vishal Thapar1, Limor Cohen6,7, Padric M Garden6,7, Yasmeen Senussi6,7, Hui Zheng10, Jill N Allen1,2, Lawrence S Blaszkowsky1,2, Jeffrey W Clark1,2, Lipika Goyal1,2, Jennifer Y Wo1,11, David P Ryan1,2, Ryan B Corcoran1,2, Vikram Deshpande1,5, Miguel N Rivera1,5, Martin J Aryee1,5, Theodore S Hong1,11, Shelley L Berger8, David R Walt6,7, Kathleen H Burns6,12, Peter J Park4, Benjamin D Greenbaum3,13, David T Ting1,2.
Abstract
Altered RNA expression of repetitive sequences and retrotransposition are frequently seen in colorectal cancer, implicating a functional importance of repeat activity in cancer progression. We show the nucleoside reverse transcriptase inhibitor 3TC targets activities of these repeat elements in colorectal cancer preclinical models with a preferential effect in p53-mutant cell lines linked with direct binding of p53 to repeat elements. We translate these findings to a human phase II trial of single-agent 3TC treatment in metastatic colorectal cancer with demonstration of clinical benefit in 9 of 32 patients. Analysis of 3TC effects on colorectal cancer tumorspheres demonstrates accumulation of immunogenic RNA:DNA hybrids linked with induction of interferon response genes and DNA damage response. Epigenetic and DNA-damaging agents induce repeat RNAs and have enhanced cytotoxicity with 3TC. These findings identify a vulnerability in colorectal cancer by targeting the viral mimicry of repeat elements. SIGNIFICANCE: Colorectal cancers express abundant repeat elements that have a viral-like life cycle that can be therapeutically targeted with nucleoside reverse transcriptase inhibitors (NRTI) commonly used for viral diseases. NRTIs induce DNA damage and interferon response that provide a new anticancer therapeutic strategy. This article is highlighted in the In This Issue feature, p. 1397. ©2022 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35320348 PMCID: PMC9167735 DOI: 10.1158/2159-8290.CD-21-1117
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 38.272